Table 3.
Distribution of Tumor Characteristics by Screening Interval, Menopausal Status, and Postmenopausal Hormone Therapy Use
| Menopausal Status | Type of Hormone Therapy Usea | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Premenopausal | Postmenopausal, without hormone therapy use | Postmenopausal, with hormone therapy use | Estrogen plus progestogen use | Estrogen only use | ||||||
| Screening Intervalb | Screening Intervalb | Screening Intervalb | Screening Intervalb | Screening Intervalb | ||||||
| Tumor Characteristic | Annual | Biennial | Annual | Biennial | Annual | Biennial | Annual | Biennial | Annual | Biennial |
| No. of breast cancers (N=11,850) | 1,525 | 502 | 5,130 | 1,353 | 2,632 | 708 | 584 | 273 | 676 | 236 |
| DCIS, % (n=2,469) | 24.1 | 27.7 | 21.6 | 16.9 | 18.9 | 18.4 | 14.4 | 15.4 | 20.3 | 19.9 |
| Invasive, % (n=9,381) | 75.9 | 72.3 | 78.4 | 83.1 | 81.1 | 81.6 | 85.6 | 84.6 | 79.7 | 80.1 |
| AJCC stage | ||||||||||
| No. of invasive cancers | 1,074 | 339 | 3,605 | 1,027 | 1,930 | 524 | 444 | 211 | 463 | 166 |
| Stage I, % | 54.2 | 46.9 | 64.4 | 63.5 | 61.9 | 61.6 | 61.0 | 62.1 | 60.0 | 60.8 |
| Stage IIA, % | 25.8 | 26.8 | 19.5 | 22.9 | 20.9 | 20.2 | 22.5 | 21.3 | 21.8 | 19.9 |
| Stage IIB, % | 10.5 | 13.6 | 9.0 | 6.8 | 8.7 | 8.4 | 8.8 | 8.5 | 9.9 | 9.0 |
| Stage III or IV, % | 9.5 | 12.7 | 7.1 | 6.8 | 8.5 | 9.7 | 7.7 | 8.1 | 8.2 | 10.2 |
| AJCC stage IIB or higherc | ||||||||||
| No. of invasive cancers | 1,095 | 346 | 3,720 | 1,071 | 1,982 | 547 | 454 | 224 | 482 | 174 |
| Yes, % | 19.8 | 25.7 | 15.8 | 13.2 | 16.9 | 17.6 | 16.1 | 16.1 | 17.6 | 18.4 |
| No, % | 80.2 | 74.3 | 84.2 | 86.8 | 83.1 | 82.4 | 83.9 | 83.9 | 82.4 | 81.6 |
| Tumor Size | ||||||||||
| No. of invasive cancers | 1,123 | 349 | 3,841 | 1,073 | 2,040 | 546 | 475 | 220 | 508 | 176 |
| <10 mm, % | 22.4 | 21.2 | 33.2 | 29.1 | 28.0 | 23.1 | 29.3 | 25.5 | 25.8 | 15.3 |
| 10 to <15 mm, % | 23.1 | 13.5 | 23.6 | 25.0 | 26.5 | 27.1 | 24.0 | 25.0 | 26.4 | 31.2 |
| 15 to 20mm, % | 24.1 | 26.9 | 18.6 | 22.6 | 22.2 | 27.5 | 22.5 | 27.3 | 21.1 | 30.1 |
| >20 mm, % | 30.5 | 38.4 | 24.6 | 23.4 | 23.3 | 22.3 | 24.2 | 22.3 | 26.8 | 23.3 |
| Lymph node | ||||||||||
| No. of invasive cancers | 1,130 | 355 | 3,882 | 1,088 | 2,066 | 556 | 479 | 224 | 511 | 180 |
| Positive, % | 31.3 | 36.6 | 21.3 | 20.7 | 26.5 | 28.4 | 25.5 | 25.0 | 26.4 | 29.4 |
| Negative, % | 68.7 | 63.4 | 78.7 | 79.3 | 73.5 | 71.6 | 74.5 | 75.0 | 73.6 | 70.6 |
| Composite measure of any less-favorable characteristicd | ||||||||||
| No. of invasive cancers | 1,105 | 349 | 3,735 | 1,062 | 1,995 | 547 | 462 | 222 | 483 | 176 |
| Any, % | 59.7 | 65.6 | 46.5 | 46.5 | 50.4 | 50.8 | 49.1 | 47.7 | 51.6 | 54 |
| None, % | 40.3 | 34.4 | 53.5 | 53.5 | 49.6 | 49.2 | 50.9 | 52.3 | 48.4 | 46 |
Abbreviation: DCIS, ductal carcinoma in situ; AJCC, American Joint Committee on Cancer.
Analysis restricted to women with known hysterectomy status. Women with a uterus were assumed to be using estrogen plus progestogen. Women without a uterus were assumed to be using estrogen only.
Annual includes cancers diagnosed within 12 months of screening exam performed 11-14 months after prior mammogram; Biennial includes cancers diagnosed within 24 months of screening exam performed 23-26 months after prior mammogram.
AJCC stage IIB or higher was imputed based on tumor size or extension, nodal status, metastasis, or SEER summary stage, when available, for women missing AJCC stage.
Stage IIB or higher, tumor size >15 mm, or positive nodes.